The publication further validates NewcelX's ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications.

The full paper can be found here.

The study, titled "Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis," was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx® addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells ("OPCs") into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model.

"This latest publication showcases the strength of our platform and proof of concept for our stem cell technology, as we aim to deliver innovative solutions across complex diseases. Furthermore, it underscores our ability to advance a broad pipeline of assets while we develop our lead candidate NCEL-101 for the treatment of type 1 diabetes," said Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX.

Key findings from the study include the potential for AstroRx® to:

  • enhance myelin debris clearance by microglia,
  • support lymphocyte-mediated immune regulation, and
  • accelerate oligodendrocyte progenitor cell ("OPC") differentiation into oligodendrocytes.